GMDA Stock Price
For anyone interested in the latest updates and insights related to GMDA stock price and news, FintechZoom provides a comprehensive platform that offers real-time information and analysis.
Stock Overview
This “Stock Overview” table offers a snapshot of a company’s performance.
Price: This is the current market value, telling you how much one share costs.
Change: This shows how much the price moved compared to yesterday, green for up, red for down.
Volume: This tells you how many shares were traded, suggesting activity and investor interest.
High/Low/Open: These show the price range during the day and where it started (open) and finished (close).
Previous Close: This is yesterday’s closing price, providing context for today’s change.
52-Week High/Low: These tell you the stock’s peak and valley over the past year, helping assess current price relative to its broader trend.
GMDA Stock News
GMDA Stock Prices Change
History of Gamida Cell Ltd.
Gamida Cell Ltd. is an Israeli biotechnology company founded in 1998 with the mission of developing and commercializing novel cell therapy products for cancer and hematological diseases. The company’s proprietary nicotinamide (NAM) technology is designed to enhance and expand innate cells, such as natural killer (NK) cells and stem cells, with the potential to offer potentially curative options for patients with blood cancers.
Early Years and Development of NAM Technology
Gamida Cell’s early years were focused on research and development, with the identification of nicotinamide (NAM) as a key molecule in cell therapy. NAM is a naturally occurring compound that plays a role in metabolic regulation and cell signaling. Gamida Cell’s scientists discovered that NAM could be used to expand and enhance the function of various types of cells, including NK cells and stem cells.
Omisirge® (Omidubicel-Onlv) for Aplastic Anemia
In 2010, Gamida Cell initiated a clinical trial of a novel cell therapy product called Omisirge® (omidubicel-onlv) for the treatment of aplastic anemia (AA), a rare blood disorder that affects the production of blood cells. AA can be life-threatening, and there are limited treatment options. Omisirge® is a stem cell product that is expanded using Gamida Cell’s NAM technology.
Clinical Trials and Regulatory Approvals
Gamida Cell has conducted extensive clinical trials of Omisirge® in patients with AA. The company has reported positive results from these trials, demonstrating the safety and efficacy of Omisirge® in treating AA. In 2021, Omisirge® was approved by the European Medicines Agency (EMA) for the treatment of AA.
Pipeline and Future Developments
In addition to Omisirge®, Gamida Cell has a pipeline of other cell therapy products in development for cancer and hematological diseases. These products are based on the company’s proprietary NAM technology and are targeting a range of unmet medical needs. Gamida Cell is committed to advancing these products through clinical development and regulatory approvals to provide patients with innovative and potentially curative therapies.
Gamida Cell Today
Today, Gamida Cell is a leading cell therapy company with a strong track record of research, development, and clinical success. The company is focused on bringing its innovative therapies to patients with cancer and hematological diseases. With its proprietary NAM technology and dedicated team, Gamida Cell is poised to make significant contributions to the future of cell therapy.
Officers and Directors
Buy GMDA Stock
FintechZoom News
GMDA Stock Price History
GMDA Stock Reddit
[wp-rss-aggregator feeds=”GMDA”]